Abstract
The bombesin (BN) receptor subtype 2 (GRP-r) is expressed in several normal human tissues and is over-expressed in various human tumors including breast, prostate, small cell lung and pancreatic cancer. Recently [{sup 99m}Tc]EDDA/HYNIC-Lys{sup 3}-bombesin ({sup 99m}Tc-HYNIC-BN) was reported as a radiopharmaceutical with high stability in human serum, specific cell GRP-r binding and rapid cell internalization. The aim of this study was to evaluate the feasibility of using {sup 99m}Tc-HYNIC-BN to image GRP-r and to assess the radiopharmaceutical biokinetics and dosimetry in 4 breast cancer patients and in 7 healthy women. Methods: Whole-body images were acquired at 20, 90, 180 min and 24 h after {sup 99m}Tc-HYNIC-BN administration. Regions of interest (ROIs) were drawn around source organs on each time frame. The same set of ROIs was used for all 11 scans and the cpm of each ROI was converted to activity using the conjugate view counting method. The image sequence was used to extrapolate {sup 99m}Tc-HYNIC-BN time-activity curves in each organ in order to calculate the total number of disintegrations (N) that occurred in the source regions, according with MIRD methodology. N data were the input for the OLINDA/EXM code to calculate internal radiation dose estimates. Results: Images showed a
More>>
Santos C, C L
[1]
- ININ, 52045 Ocoyoacac, Estado de Mexico (Mexico)
Citation Formats
Santos C, C L.
Biokinetics and dosimetry in patients of {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesin: images of GRP receptors; Biocinetica y dosimetria en humanos de {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesina: imagenes de receptores GRP.
Mexico: N. p.,
2007.
Web.
Santos C, C L.
Biokinetics and dosimetry in patients of {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesin: images of GRP receptors; Biocinetica y dosimetria en humanos de {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesina: imagenes de receptores GRP.
Mexico.
Santos C, C L.
2007.
"Biokinetics and dosimetry in patients of {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesin: images of GRP receptors; Biocinetica y dosimetria en humanos de {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesina: imagenes de receptores GRP."
Mexico.
@misc{etde_21219278,
title = {Biokinetics and dosimetry in patients of {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesin: images of GRP receptors; Biocinetica y dosimetria en humanos de {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesina: imagenes de receptores GRP}
author = {Santos C, C L}
abstractNote = {The bombesin (BN) receptor subtype 2 (GRP-r) is expressed in several normal human tissues and is over-expressed in various human tumors including breast, prostate, small cell lung and pancreatic cancer. Recently [{sup 99m}Tc]EDDA/HYNIC-Lys{sup 3}-bombesin ({sup 99m}Tc-HYNIC-BN) was reported as a radiopharmaceutical with high stability in human serum, specific cell GRP-r binding and rapid cell internalization. The aim of this study was to evaluate the feasibility of using {sup 99m}Tc-HYNIC-BN to image GRP-r and to assess the radiopharmaceutical biokinetics and dosimetry in 4 breast cancer patients and in 7 healthy women. Methods: Whole-body images were acquired at 20, 90, 180 min and 24 h after {sup 99m}Tc-HYNIC-BN administration. Regions of interest (ROIs) were drawn around source organs on each time frame. The same set of ROIs was used for all 11 scans and the cpm of each ROI was converted to activity using the conjugate view counting method. The image sequence was used to extrapolate {sup 99m}Tc-HYNIC-BN time-activity curves in each organ in order to calculate the total number of disintegrations (N) that occurred in the source regions, according with MIRD methodology. N data were the input for the OLINDA/EXM code to calculate internal radiation dose estimates. Results: Images showed a rapid radiopharmaceutical blood clearance with renal excretion as predominant route. {sup 99m}Tc-HYNIC-BN exhibited high in vivo affinity for GRP-r over-expression successfully visualized in cancer mammary glands and well differentiated from the ubiquitous GRP-r expression in normal breast, lungs and airways. There was no statistically significant difference (p > 0.05) in the radiation absorbed doses between cancer patients and healthy women. The average equivalent doses (n=11) for a study using 740 MBq were 24.8 +- 8.8 mSv (kidneys), 7.3 +- 1.8 mSv (lungs), 6.5 +- 4.0 mSv (breast) 2.0 +- 0.3 mSv (pancreas), 1.6 +- 0.3 mSv (liver), 1.2 +- 0.2 mSv (ovaries) and 1.0 +- 0.2 mSv (red marrow). The mean effective dose was 3.3 +- 0.6 mSv. Conclusions: The highest absorbed dose variability was found in breast tissues because of differences in the in vivo affinity for GRP-r over-expression. All the absorbed doses are comparable with that known for most of the {sup 99m}Tc studies. In spite of the ubiquitous GRP-r expression in non-neoplastic tissues {sup 99m}Tc-HYNIC-BN is as a promising imaging radiopharmaceutical to target site-specific early breast cancer. These results warrant a further clinical study. (Author)}
place = {Mexico}
year = {2007}
month = {Jul}
}
title = {Biokinetics and dosimetry in patients of {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesin: images of GRP receptors; Biocinetica y dosimetria en humanos de {sup 99m}Tc-HYNIC-Lys{sup 3}-Bombesina: imagenes de receptores GRP}
author = {Santos C, C L}
abstractNote = {The bombesin (BN) receptor subtype 2 (GRP-r) is expressed in several normal human tissues and is over-expressed in various human tumors including breast, prostate, small cell lung and pancreatic cancer. Recently [{sup 99m}Tc]EDDA/HYNIC-Lys{sup 3}-bombesin ({sup 99m}Tc-HYNIC-BN) was reported as a radiopharmaceutical with high stability in human serum, specific cell GRP-r binding and rapid cell internalization. The aim of this study was to evaluate the feasibility of using {sup 99m}Tc-HYNIC-BN to image GRP-r and to assess the radiopharmaceutical biokinetics and dosimetry in 4 breast cancer patients and in 7 healthy women. Methods: Whole-body images were acquired at 20, 90, 180 min and 24 h after {sup 99m}Tc-HYNIC-BN administration. Regions of interest (ROIs) were drawn around source organs on each time frame. The same set of ROIs was used for all 11 scans and the cpm of each ROI was converted to activity using the conjugate view counting method. The image sequence was used to extrapolate {sup 99m}Tc-HYNIC-BN time-activity curves in each organ in order to calculate the total number of disintegrations (N) that occurred in the source regions, according with MIRD methodology. N data were the input for the OLINDA/EXM code to calculate internal radiation dose estimates. Results: Images showed a rapid radiopharmaceutical blood clearance with renal excretion as predominant route. {sup 99m}Tc-HYNIC-BN exhibited high in vivo affinity for GRP-r over-expression successfully visualized in cancer mammary glands and well differentiated from the ubiquitous GRP-r expression in normal breast, lungs and airways. There was no statistically significant difference (p > 0.05) in the radiation absorbed doses between cancer patients and healthy women. The average equivalent doses (n=11) for a study using 740 MBq were 24.8 +- 8.8 mSv (kidneys), 7.3 +- 1.8 mSv (lungs), 6.5 +- 4.0 mSv (breast) 2.0 +- 0.3 mSv (pancreas), 1.6 +- 0.3 mSv (liver), 1.2 +- 0.2 mSv (ovaries) and 1.0 +- 0.2 mSv (red marrow). The mean effective dose was 3.3 +- 0.6 mSv. Conclusions: The highest absorbed dose variability was found in breast tissues because of differences in the in vivo affinity for GRP-r over-expression. All the absorbed doses are comparable with that known for most of the {sup 99m}Tc studies. In spite of the ubiquitous GRP-r expression in non-neoplastic tissues {sup 99m}Tc-HYNIC-BN is as a promising imaging radiopharmaceutical to target site-specific early breast cancer. These results warrant a further clinical study. (Author)}
place = {Mexico}
year = {2007}
month = {Jul}
}